Evidence map›Paper›PMID 31480541›Full record

ArticleMolecules (Basel, Switzerland)2019

DMPK is a New Candidate Mediator of Tumor Suppressor p53-Dependent Cell Death.

Katsuhiko Itoh, Takahiro Ebata, Hiroaki Hirata, Takeru Torii, Wataru Sugimoto, Keigo Onodera, Wataru Nakajima, Ikuno Uehara, Daisuke Okuzaki, Shota Yamauchi and 4 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Prostate Cancer Secretome and Membrane Proteome fromInternational journal of molecular sciences · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Katsuhiko ItohFrontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe 650-0047, Japan.
Takahiro EbataFrontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe 650-0047, Japan.
Hiroaki HirataMechanobiology Laboratory, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.ORCID 0000-0002-2604-9158
Takeru ToriiFrontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe 650-0047, Japan.
Wataru SugimotoFrontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe 650-0047, Japan.ORCID 0000-0002-7381-1862
Keigo OnoderaDepartment of Molecular Oncology, Institute for Advanced Medical Sciences, Nippon Medical School, Tokyo 113-8602, Japan.
Wataru NakajimaDepartment of Molecular Oncology, Institute for Advanced Medical Sciences, Nippon Medical School, Tokyo 113-8602, Japan.
Ikuno UeharaDepartment of Molecular Oncology, Institute for Advanced Medical Sciences, Nippon Medical School, Tokyo 113-8602, Japan.
Daisuke OkuzakiGenome information research center, Research institute for microbial diseases, Osaka University, Osaka 565-0871, Japan.ORCID 0000-0002-4552-783X
Shota YamauchiGraduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo 113-0033, Japan.
Yemima BudirahardjaFrontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe 650-0047, Japan.
Takahito NishikataFrontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe 650-0047, Japan.
Nobuyuki TanakaDepartment of Molecular Oncology, Institute for Advanced Medical Sciences, Nippon Medical School, Tokyo 113-8602, Japan.
Keiko KawauchiFrontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe 650-0047, Japan. kawauchi@konan-u.ac.jp.ORCID 0000-0002-8276-7277
Konan University · JPNippon Medical School · JPNagoya University · JPThe University of Osaka · JPThe University of Tokyo · JP

Funding

Japan Society for the Promotion of Science JPH04054 and JP18K06231The Nakatomi Foundation, the Naito Foundation, and the HIRAO TARO Foundation of Konan University N.A.
6 · The paper itself

Abstract

Tumor suppressor p53 plays an integral role in DNA-damage induced apoptosis, a biological process that protects against tumor progression. Cell shape dramatically changes when cells undergo apoptosis, which is associated with actomyosin contraction; however, it remains entirely elusive how p53 regulates actomyosin contraction in response to DNA-damaging agents. To identify a novel p53 regulating gene encoding the modulator of myosin, we conducted DNA microarray analysis. We found that, in response to DNA-damaging agent doxorubicin, expression of myotonic dystrophy protein kinase (DMPK), which is known to upregulate actomyosin contraction, was increased in a p53-dependent manner. The promoter region of DMPK gene contained potential p53-binding sequences and its promoter activity was increased by overexpression of the p53 family protein p73, but, unexpectedly, not of p53. Furthermore, we found that doxorubicin treatment induced p73 expression, which was significantly attenuated by downregulation of p53. These data suggest that p53 induces expression of DMPK through upregulating p73 expression. Overexpression of DMPK promotes contraction of the actomyosin cortex, which leads to formation of membrane blebs, loss of cell adhesion, and concomitant caspase activation. Taken together, our results suggest the existence of p53-p73-DMPK axis which mediates DNA-damage induced actomyosin contraction at the cortex and concomitant cell death.

Indexed as

AnimalsCaspasesCell AdhesionCell DeathDoxorubicinEnzyme ActivationFibroblastsHumansMCF-7 CellsMiceMyotonin-Protein KinasePromoter Regions, GeneticTumor Protein p73Tumor Suppressor Protein p53CaspasesDMPK protein, mouseDoxorubicinMyotonin-Protein KinaseTumor Protein p73Tumor Suppressor Protein p53actinDMPKmyosinp53p73

Identifiers

PMID31480541
PMCPMC6749264
OpenAlexW2970174529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.